% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Guglielmo:283177,
      author       = {P. Guglielmo and P. Alongi and L. Baratto and E. Abenavoli
                      and A. Buschiazzo and G. Celesti and M. Conte and R. Filice
                      and J. Gorica and L. Jonghi-Lavarini and H. Lanzafame$^*$
                      and R. Laudicella and M. Librando and F. Linguanti and F.
                      Mattana and A. Miceli and L. Olivari and L. Piscopo and C.
                      Romagnolo and G. Santo and A. Vento and F. Volpe and L.
                      Evangelista},
      title        = {{H}ead-to-{H}ead {C}omparison of {FDG} and {R}adiolabeled
                      {FAPI} {PET}: {A} {S}ystematic {R}eview of the
                      {L}iterature.},
      journal      = {Life},
      volume       = {13},
      number       = {9},
      issn         = {2075-1729},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-01956},
      pages        = {1821},
      year         = {2023},
      abstract     = {FAPI-based radiopharmaceuticals are a novel class of
                      tracers, mainly used for PET imaging, which have
                      demonstrated several advantages over [18F]FDG, especially in
                      the case of low-grade or well-differentiated tumors. We
                      conducted this systematic review to evaluate all the studies
                      where a head-to-head comparison had been performed to
                      explore the potential utility of FAPI tracers in clinical
                      practice. FAPI-based radiopharmaceuticals have shown
                      promising results globally, in particular in detecting
                      peritoneal carcinomatosis, but studies with wider
                      populations are needed to better understand all the
                      advantages of these new radiopharmaceuticals.},
      subtyp        = {Review Article},
      keywords     = {FDG (Other) / PET/CT (Other) / PET/MRI (Other) / fibroblast
                      activation protein inhibitor (FAPI) (Other) / hybrid imaging
                      (Other) / molecular imaging (Other) / new radiotracers
                      (Other) / nuclear medicine (Other) / theranostics (Other)},
      cin          = {ED01},
      ddc          = {570},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37763225},
      doi          = {10.3390/life13091821},
      url          = {https://inrepo02.dkfz.de/record/283177},
}